Prior studies primarily explored high-dose Anakinra (400 mg daily or 8 mg/kg/day) for severe or steroid-refractory MAS, making this case significant in showing that early IL-1 blockade at a lower dose may prevent escalation to high-dose immunosuppression. This evidence concerns the gene IL1B and macrophage activation syndrome.